<DOC>
	<DOCNO>NCT00038597</DOCNO>
	<brief_summary>The goal research see give drug SCH66336 mouth improve disease patient chronic accelerated phase CML . The safety treatment also study .</brief_summary>
	<brief_title>Phase II Study SCH66336 , A Farnesyltransferase Inhibitor Chronic Myelogenous Leukemia ( CML )</brief_title>
	<detailed_description>Objectives study two-fold : 1 . To determine efficacy SCH66336 patient chronic phase accelerate phase CML relation response rate , duration response , survival . 2 . To assess toxicity SCH66366 patient .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<criteria>Diagnosis Philadelphia chromosome ( Ph ) positive CML chronic accelerate phase ; Failure respond intolerance imatinib mesylate ( Gleevec ) ; Age &gt; /= 16 year ; Life expectancy &gt; /= 2 month ; Performance status 2 better ( Zubrod ) ; Adequate renal hepatic function ( creatinine bilirubin &lt; /= 2 mg/dl ) ; Adequate cardiac function ; Not candidate refuse allogeneic transplantation ; Patients receive azoles ( ketoconazole , itraconazole , fluconazole ) , macrolides , HIV protease inhibitor , cyclosporin antiseizure drug ( phenobarbital , phenytoin , carbamazepine ) , rifampin isoniazid .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Philadelphia chromosome positive CML</keyword>
	<keyword>Myelogenous Leukemia , Chronic , Chronic Phase</keyword>
	<keyword>Myelogenous Leukemia , Chronic , Accelerated Phase</keyword>
</DOC>